Our second priority was to build our hematological oncology franchise into a major growth engine for the Company. IMBRUVICA and VENCLEXTA have become roughly a $5.5 billion franchise, and growing rapidly. And we continue to expand these medicines into important new disease areas, such as multiple myeloma with VENCLEXTA in t(11;14) biomarker-defined patient population, and combination therapy with IMBRUVICA and VENCLEXTA, which have the potential to provide even deeper and more durable responses.